• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
  • View Item
  •   LillOA Home
  • Liste des unités
  • Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Utility of (18)fluoro-deoxyglucose positron ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique
DOI :
10.1093/annonc/mdv010
PMID :
25605745
Permalink :
http://hdl.handle.net/20.500.12210/4403
Title :
Utility of (18)fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma
Author(s) :
Horwitz, SM [Auteur]
Coiffier, Bertrand [Auteur]
Foss, FM [Auteur]
Prince, HM [Auteur]
Sokol, L [Auteur]
Greenwood, M [Auteur]
Caballero, Dolores [Auteur]
Morschhauser, Franck [Auteur] refId
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Pinter-Brown, L [Auteur]
Iyer, SP [Auteur]
Shustov, A [Auteur]
Nichols, J [Auteur]
Balser, J [Auteur]
Balser, BE [Auteur]
Pro, B [Auteur]
Journal title :
Annals of oncology
Abbreviated title :
Ann. Oncol.
Volume number :
26
Pages :
774-779
Publication date :
2015
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
BACKGROUND: For patients with peripheral T-cell lymphoma (PTCL), the value of (18)fluoro-deoxyglucose positron emission tomography (FDG-PET) scans for assessing prognosis and response to treatment remains unclear. The ...
Show more >
BACKGROUND: For patients with peripheral T-cell lymphoma (PTCL), the value of (18)fluoro-deoxyglucose positron emission tomography (FDG-PET) scans for assessing prognosis and response to treatment remains unclear. The utility of FDG-PET, in addition to conventional radiology, was examined as a planned exploratory end point in the pivotal phase 2 trial of romidepsin for the treatment of relapsed/refractory PTCL. PATIENTS AND METHODS: Patients received romidepsin at a dose of 14 mg/m(2) on days 1, 8, and 15 of 28-day cycles. The primary end point was the rate of confirmed/unconfirmed complete response (CR/CRu) as assessed by International Workshop Criteria (IWC) using conventional radiology. For the exploratory PET end point, patients with at least baseline FDG-PET scans were assessed by IWC + PET criteria. RESULTS: Of 130 patients, 110 had baseline FDG-PET scans, and 105 were PET positive at baseline. The use of IWC + PET criteria increased the objective response rate to 30% compared with 26% by conventional radiology. Durations of response were well differentiated by both conventional radiology response criteria [CR/CRu versus partial response (PR), P = 0.0001] and PET status (negative versus positive, P < 0.0001). Patients who achieved CR/CRu had prolonged progression-free survival (PFS, median 25.9 months) compared with other response groups (P = 0.0007). Patients who achieved PR or stable disease (SD) had similar PFS (median 7.2 and 6.3 months, respectively, P = 0.6427). When grouping PR and SD patients by PET status, patients with PET-negative versus PET-positive disease had a median PFS of 18.2 versus 7.1 months (P = 0.0923). CONCLUSIONS: Routine use of FDG-PET does not obviate conventional staging, but may aid in determining prognosis and refine response assessments for patients with PTCL, particularly for those who do not achieve CR/CRu by conventional staging. The optimal way to incorporate FDG-PET scans for patients with PTCL remains to be determined. TRIAL REGISTRATION: NCT00426764.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
CHU Lille
Collections :
  • Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Research team(s) :
Innovation/évaluation des médicaments injectables
Submission date :
2019-02-26T17:07:42Z
Université de Lille

Mentions légales
Université de Lille © 2017